Page last updated: 2024-12-07

gp 1-515

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GP 1-515: an adenosine kinase inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132663
CHEMBL ID356141
SCHEMBL ID2053010
MeSH IDM0232229

Synonyms (20)

Synonym
4-amino-1-(5-amino-5-deoxy-1-beta-d-ribofuranosyl)-3-bromopyrazolo(3,4-d)pyrimidine
unii-12dpv3l6jd
144928-48-3
gp 1-515
1-(5-amino-5-deoxy-beta-d-ribofuranosyl)-3-bromo-1h-pyrazolo(3,4-d)pyrimidin-4-amine
1h-pyrazolo(3,4-d)pyrimidin-4-amine, 1-(5-amino-5-deoxy-beta-d-ribofuranosyl)-3-bromo-
gp-1-515
12dpv3l6jd ,
gp515
(2s,3s,4r,5s)-2-(4-amino-3-bromo-pyrazolo[3,4-d]pyrimidin-1-yl)-5-aminomethyl-tetrahydro-furan-3,4-diol
bdbm50134744
CHEMBL356141 ,
adenosine kinase inhibitor gp515
(2r,3r,4s,5r)-2-(4-amino-3-bromopyrazolo[3,4-d]pyrimidin-1-yl)-5-(aminomethyl)oxolane-3,4-diol
SCHEMBL2053010
gp-515
DTXSID30162847
1-(5-amino-5-deoxy-.beta.-d-ribofuranosyl)-3-bromo-1h-pyrazolo(3,4-d)pyrimidin-4-amine
(2r,3r,4s,5r)-2-(4-amino-3-bromo-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-5-(aminomethyl)tetrahydrofuran-3,4-diol
1h-pyrazolo(3,4-d)pyrimidin-4-amine, 1-(5-amino-5-deoxy-.beta.-d-ribofuranosyl)-3-bromo-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine kinaseHomo sapiens (human)IC50 (µMol)0.00400.00050.605210.0000AID33984
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
purine ribonucleoside salvageAdenosine kinaseHomo sapiens (human)
dATP biosynthetic processAdenosine kinaseHomo sapiens (human)
ribonucleoside monophosphate biosynthetic processAdenosine kinaseHomo sapiens (human)
GMP salvageAdenosine kinaseHomo sapiens (human)
AMP salvageAdenosine kinaseHomo sapiens (human)
dAMP salvageAdenosine kinaseHomo sapiens (human)
purine nucleobase metabolic processAdenosine kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
RNA bindingAdenosine kinaseHomo sapiens (human)
deoxyadenosine kinase activityAdenosine kinaseHomo sapiens (human)
ATP bindingAdenosine kinaseHomo sapiens (human)
metal ion bindingAdenosine kinaseHomo sapiens (human)
adenosine kinase activityAdenosine kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleoplasmAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
plasma membraneAdenosine kinaseHomo sapiens (human)
nucleusAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID33984Inhibitory activity against human recombinant adenosine kinase2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Adenosine kinase inhibitors. 3. Synthesis, SAR, and antiinflammatory activity of a series of l-lyxofuranosyl nucleosides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (62.50)18.2507
2000's3 (37.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]